160 related articles for article (PubMed ID: 17764960)
21. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
[TBL] [Abstract][Full Text] [Related]
22. [SCA 40 and derivatives: new bronchodilators in an imidazo(1,2-a)pyrazine series].
Bonnet PA; Vitse O; Bénezech V; Subra G; Fabréguettes JR; Zanik L; Laurent F; Michel A; Bompart J; Chapat JP
Ann Pharm Fr; 1998; 56(4):155-9. PubMed ID: 9770008
[TBL] [Abstract][Full Text] [Related]
23. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
Niculescu-Duvaz I; Roman E; Whittaker SR; Friedlos F; Kirk R; Scanlon IJ; Davies LC; Niculescu-Duvaz D; Marais R; Springer CJ
J Med Chem; 2006 Jan; 49(1):407-16. PubMed ID: 16392826
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.
Burns CJ; Harte MF; Bu X; Fantino E; Giarrusso M; Joffe M; Kurek M; Legge FS; Razzino P; Su S; Treutlein H; Wan SS; Zeng J; Wilks AF
Bioorg Med Chem Lett; 2009 Feb; 19(4):1206-9. PubMed ID: 19128971
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Schmitz WD; Molski TF; Mattson GK; Lodge NJ; Bronson JJ; Macor JE
Bioorg Med Chem Lett; 2010 Mar; 20(6):1890-4. PubMed ID: 20176478
[TBL] [Abstract][Full Text] [Related]
26. Piperidine derivatives as nonprostanoid IP receptor agonists.
Hayashi R; Sakagami H; Koiwa M; Ito H; Miyamoto M; Isogaya M
Bioorg Med Chem Lett; 2016 May; 26(9):2360-4. PubMed ID: 26996371
[TBL] [Abstract][Full Text] [Related]
27. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
[TBL] [Abstract][Full Text] [Related]
28. Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.
Hattori K; Takamura F; Tanaka A; Takasugi H; Taniguchi K; Nishio M; Koyama S; Seki J; Sakane K
Bioorg Med Chem Lett; 2005 Jul; 15(13):3284-7. PubMed ID: 15935659
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.
Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
Bioorg Med Chem Lett; 2013 Jul; 23(13):3857-63. PubMed ID: 23719231
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationships of pyrazine-based CK2 inhibitors: synthesis and evaluation of 2,6-disubstituted pyrazines and 4,6-disubstituted pyrimidines.
Suzuki Y; Cluzeau J; Hara T; Hirasawa A; Tsujimoto G; Oishi S; Ohno H; Fujii N
Arch Pharm (Weinheim); 2008 Sep; 341(9):554-61. PubMed ID: 18763715
[TBL] [Abstract][Full Text] [Related]
31. Ligustrazine derivatives. Part 4: design, synthesis, and biological evaluation of novel ligustrazine-based stilbene derivatives as potential cardiovascular agents.
Deng L; Guo X; Zhai L; Song Y; Chen H; Zhan P; Wu J; Liu X
Chem Biol Drug Des; 2012 May; 79(5):731-9. PubMed ID: 22251434
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.
Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
Bioorg Med Chem Lett; 2013 Apr; 23(7):2212-6. PubMed ID: 23434414
[TBL] [Abstract][Full Text] [Related]
33. Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.
Hattori K; Tanaka A; Okitsu O; Tabuchi S; Taniguchi K; Nishio M; Koyama S; Higaki M; Seki J; Sakane K
Bioorg Med Chem Lett; 2005 Jun; 15(12):3091-5. PubMed ID: 15914004
[TBL] [Abstract][Full Text] [Related]
34. 5-HT2C receptor agonists with potential anorectic activity.
Yoon G; Jeong HJ; Kim JJ; Cheon SH
Arch Pharm Res; 2008 Aug; 31(8):989-94. PubMed ID: 18787786
[TBL] [Abstract][Full Text] [Related]
35. Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.
Arban R; Bianchi F; Buson A; Cremonesi S; Di Fabio R; Gentile G; Micheli F; Pasquarello A; Pozzan A; Tarsi L; Terreni S; Tonelli F
Bioorg Med Chem Lett; 2010 Sep; 20(17):5044-9. PubMed ID: 20674355
[TBL] [Abstract][Full Text] [Related]
36. Pyrazine derivatives: a patent review (2008 - present).
Ferreira SB; Kaiser CR
Expert Opin Ther Pat; 2012 Sep; 22(9):1033-51. PubMed ID: 22860922
[TBL] [Abstract][Full Text] [Related]
37. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations.
Moulin A; Demange L; Ryan J; Mousseaux D; Sanchez P; Bergé G; Gagne D; Perrissoud D; Locatelli V; Torsello A; Galleyrand JC; Fehrentz JA; Martinez J
J Med Chem; 2008 Feb; 51(3):689-93. PubMed ID: 18193826
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Aoki T; Asaki T; Hamamoto T; Sugiyama Y; Ohmachi S; Kuwabara K; Murakami K; Todo M
Bioorg Med Chem Lett; 2008 Mar; 18(6):2128-32. PubMed ID: 18280733
[TBL] [Abstract][Full Text] [Related]
39. New cyclic somatostatin analogues containing a pyrazinone ring: importance of Tyr for antiproliferative activity.
Miyazaki A; Tsuda Y; Fukushima S; Yokoi T; Vántus T; Bökönyi G; Szabó E; Horváth A; Kéri G; Okada Y
Bioorg Med Chem Lett; 2008 Dec; 18(23):6199-201. PubMed ID: 18930401
[TBL] [Abstract][Full Text] [Related]
40. Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors.
García J; Khanwalkar H; Pereira R; Erb C; Voegel JJ; Collette P; Mauvais P; Bourguet W; Gronemeyer H; de Lera AR
Chembiochem; 2009 May; 10(7):1252-9. PubMed ID: 19343742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
